E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammation of the gum tissue |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the efficacy of Listerine®Advanced Defence Gum Treatment (a mouthwash classified as Class IIa medical device already on the market in the EU) on whole-mouth mean gingival bleeding index (BI) scores as an adjunct to brushing through four week of use and to determine whether its performance is comparable to that of an established gingivitis treatment (i.e. Corsodyl® Mint Mouthwash). |
|
E.2.2 | Secondary objectives of the trial |
To determine the efficacy of a LAE-containing mouth rinse on wholemouth mean modified gingival index (MGI) and plaque index (PI) scores as an adjunct to brushing through one week, two weeks and four weeks of use. To determine the efficacy of a LAE-containing mouth rinse on whole mouth mean bleeding index (BI) score as an adjunct to brushing through one week and two weeks of use. To determine the effect of a LAE-containing mouth rinse as an adjunct to brushing on extrinsic staining assessment at two and four weeks. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Males and females 18 years of age or older. 2.A minimum of 20 natural teeth with scorable facial and lingual surfaces. Teeth that are grossly carious, extensively restored, orthodontically banded, abutments, exhibiting severe generalized cervical and/or enamel abrasion, or third molars will not be included in the tooth count. 3.A mean gingival index ≥ 1.75 according to the Modified Gingival Index. 4.A mean plaque index ≥ 1.95 according to the Turesky modification of the Quigley-Hein Plaque Index scored on six surfaces per tooth. 5.Bleeding Index ≥ 0.15. 6.Absence of significant oral soft tissue pathology, excluding plaque induced gingivitis, based on a visual examination and at the discretion of the Investigator. 7.Absence of moderate/advanced periodontitis based on a clinical examination (ADA Type III, IV). 8.Absence of fixed or removable orthodontic appliance or removable partial dentures. 9.Evidence of a personally signed and dated informed consent document. |
|
E.4 | Principal exclusion criteria |
1.Known sensitivity to the investigational product ingredients. 2.Self-reported pregnancy or lactation. 3.Dental prophylaxis within 2 weeks prior to Screening visit. 4.History of medical conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures. 5.Antibiotic, anti-inflammatory or anticoagulant therapy during the study or within the one month prior to the baseline exam. Intermittent use of certain anti-inflammatory medication is acceptable at the discretion of the investigator. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable is the whole-mouth mean Bleeding Index (BI) at four weeks |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline and 4 weeks after treatment |
|
E.5.2 | Secondary end point(s) |
1.Whole mouth mean modified gingival index (MGI) and plaque index (PI) 2.Whole-mouth mean bleeding index (BI) 3.Extrinsic stain assessment at two and four weeks |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1.Whole mouth mean PI and MGI measured at one week, two weeks and four weeks. 2.BI at one and two weeks. 3.Extrinsic stain assessment at two and four weeks. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 7 |